1、 Pharmaceuticals and Healthcare Report Code:GDPH58486FSA Published:August 2024 Amarin Corp Plc(AMRN)-Financial and Strategic SWOT Analysis Review Amarin Corp Plc(AMRN)-Financial and Strategic SWOT Analysis Review Report Code:GDPH58486FSA Published:August 2024 GlobalData 2024.This product is licensed

2、 and is not to be photocopied.Page 2 Company Snapshot 88 Harcourt Street Phone+353 1 6699020 Revenue 306.9(million USD)Dublin,Dublin Fax Net Profit-59.11(million USD)Website Employees 275 Ireland Exchange AMRN NASDAQ Industry Pharmaceuticals&Healthcare Company Overview Amarin Corp Plc(Amarin)is a ph

3、armaceutical company which develops and commercializes medicines for cardiovascular diseases.The companys lead product,Vascepa(icosapent ethyl),is a single-molecule prescription capsule used as an adjunct to diet for the reduction of triglyceride levels in adult patients with severe hypertriglycerid

4、emia and high triglyceride levels or mixed dyslipidemia and cardiovascular risk.Amarin is also evaluating Vascepa as an add-on therapy to reduce major cardiovascular events in an at-risk patient population on statin therapy.The company markets the product in the US through wholesalers and specialty

5、pharmacy providers.Key Executives Name Title Per Wold-Olsen Chairman Oliver OConnor Director Patrice Bonfiglio Director Paul Cohen Director Mark DiPaolo Director Source:Annual Report,Company Website,Primary and Secondary Research,GlobalData Share Data Amarin Corp Plc Share Price(USD)as on 02-Aug-202

6、4 0.60 EPS(USD)-0.06 Market Cap(million USD)263 Enterprise Value(million USD)-58 Shares Outstanding(million)411 Source:Annual Report,Company Website,Primary and Secondary Research,GlobalData SWOT Analysis Amarin Corp Plc,SWOT Analysis Strengths Weaknesses Focus on R&D Activities Lead Product:VASCEPA